Guiyang Xintian Pharmaceutical Hits Day Low Amid Price Pressure at CNY 8.84

Guiyang Xintian Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 8.4% and reaching an intraday low of CNY 8.84. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by 3.63% on the same day. Over the past week, Guiyang Xintian has seen a 14.29% decrease, while its monthly performance reflects a decline of 14.94%. Year-to-date, the stock has also underperformed, with a loss of 9.88%, compared to the China Shanghai Composite's decline of 3.92%. The company's long-term growth prospects appear limited, as evidenced by a net sales decline of 24.41% in the most recent half-year period and a significant drop in pre-tax profit by 67.71%. With a market capitalization of CNY 2,327 million, Guiyang Xintian operates within the pharmaceuticals and biotechnology sector. The company has reported negative results for the last ten consecutive quarters, contributing to its consistent underperformance against the benchmark over the past three years. The current price-to-earnings ratio stands at 93.00, indicating a high valuation relative to its earnings.